New alert system aims to cut unnecessary antibiotics in pneumonia patients

NCT ID NCT05976581

Completed Knowledge-focused Sponsor: Jonathan Baghdadi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether electronic alerts and structured messages from an antibiotic stewardship team could reduce antibiotic use in hospitalized patients with suspected pneumonia. 107 adults were enrolled, and those with test results suggesting viral infection were randomly assigned to receive a recommendation to stop or reduce antibiotics or to usual care. The goal was to see if this approach could safely cut down on unnecessary antibiotics.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: electronic alert and structured communication
What this could lead to: If successful, this approach could help hospitals use antibiotics more wisely, reducing side effects and antibiotic resistance.
What could go wrong: This is a small, completed study with 107 participants, so results may not apply to all hospitals or patients. The intervention is behavioral, not a new drug, so impact may be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial pneumonia pneumonia viral pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMONIA PNEUMONIA, BACTERIAL PNEUMONIA, VIRAL

Contacts and locations

Locations

University of Maryland Medical Center

Baltimore, Maryland, 21201, United States
University of Maryland Medical Center - Midtown Campus

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.